Related Experiment Videos
Growth factor-assisted chemotherapy--the Manchester experience
D Crowther1, J H Scarffe, A Howell
1Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
Ciba Foundation Symposium
|January 1, 1990
Summary
Granulocyte colony-stimulating factors (G-CSF and GM-CSF) significantly shorten neutropenia after chemotherapy, reducing infection risk. These growth factors enable more frequent, intensive chemotherapy regimens, improving patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Colony-stimulating factors (CSFs) like erythropoietin, G-CSF, and GM-CSF stimulate blood cell production.
- Previous studies demonstrated CSF efficacy in stimulating red cell and granulocyte production.
- G-CSF was the first human CSF shown to reduce neutropenia and infection risk post-chemotherapy.
Purpose of the Study:
- To evaluate the efficacy of G-CSF in shortening neutropenia following intensive chemotherapy.
- To investigate the feasibility of using G-CSF to enable more frequent, high-dose chemotherapy.
- To assess GM-CSF's role in reducing neutropenia after high-dose Melphalan without autologous bone marrow transplantation.
Main Methods:
- A study in Manchester used G-CSF to treat neutropenia after combination chemotherapy.
- A subsequent study administered Doxorubicin followed by G-CSF infusion for 11 days.
- GM-CSF was administered via continuous intravenous infusion after high-dose Melphalan.
Main Results:
- G-CSF significantly shortened neutropenia by a median of 80%, restoring neutrophil counts within 14 days.
- High-dose chemotherapy cycles with G-CSF support were delivered every 14 days.
- GM-CSF reduced the period of severe neutropenia (<500 cells/mm³) to less than 15 days post-Melphalan, avoiding ABMT.
Conclusions:
- Intensive chemotherapy with dose-limiting myelosuppression can be administered more frequently with G-CSF support.
- GM-CSF can reduce life-threatening neutropenia following high-dose Melphalan, potentially obviating the need for ABMT.
- Further research is needed to optimize G-CSF and GM-CSF dosing schedules and explore combined bioregulator use.